25. April 2018
Amanda Ebbutt and Louisa Penny report the findings of the European Commission's 8th Report on the monitoring of patent settlements in the pharmaceutical sector.
Paul England explains how there are three exemptions in the UK that potentially apply to patent infringement by life sciences products.
Belinda Lavin considers a recent General Court decision concerning the requirements for designation of a medicinal product as an orphan medicinal product.
Matthew Royle and Paul England discuss the impact that the draft Brexit withdrawal and transition arrangements have on life sciences products.
Sara Burghart and Paul England discuss the latest status in the UK and Germany of the ratification of the Unified Patent Court and Unitary Patent.
von mehreren Autoren